References
- Biogen Netherlands B.V. Tysabri® (natalizumab). Summary of Product Characteristics, 2022. [Internet]. [cited 2023 Apr 6]. Available from: https://www.ema.europa.eu/documents/product-information/tysabri-epar-product-information_en.pdf.
- Biogen Inc. Tysabri® (natalizumab). Prescribing Information. [Internet]. 2023 [cited 2023 Oct 2]. Available from: https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf
- Sheremata WA, Minagar A, Alexander JS, et al. The role of alpha-4 integrin in the aetiology of multiple sclerosis. CNS Drugs. 2005;19(11):909–922.
- Saure C, Warnke C, Zohren F, et al. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol. 2011;68:1428–1431. doi: 10.1001/archneurol.2011.238
- Warnke C, Stettner M, Lehmensiek V, et al. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Mult Scler. 2015;21(8):1036–1044.
- McCamish M, Yoon W, McKay J. Biosimilars: biologics that meet patients’ needs and healthcare economics. Am J Manag Care. 2016;22:S439–S442. 13 Suppl
- IMS Health for Healthcare Informatics. Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. [Internet]. 2016 [cited2023 Apr 6]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2016/03/IMS-Institute-Biosimilar-Report-March-2016-FINAL.pdf
- Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5(1):e000900.
- Gherghescu I, Delgado-Charro MB. The biosimilar landscape: an overview of regulatory approvals by the EMA and FDA. Pharmaceutics. 2020;13(1):48. doi: 10.3390/pharmaceutics13010048
- IQVIA. The impact of biosimilar competition in Europe. [Internet]. 2021 [cited 2021 Apr 6]. Available from:https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021
- Kurki P, Kang H-N, Ekman N, et al. Regulatory Evaluation of Biosimilars: refinement of principles based on the scientific evidence and clinical experience. BioDrugs. 2022;36(3):359–371.
- Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621–634.
- Cohen HP, Lamanna WC, Schiestl M. Totality of evidence and the role of clinical studies in establishing biosimilarity. In: Gutka H, Yang H, and Kakar S, editors Biosimilars: regulatory, clinical, and biopharmaceutical development. Cham: Springer; 2018. p. 601–628. doi: 10.1007/978-3-319-99680-6_22
- Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–5117.
- FDA. Biosimilar and interchangeable Biologics: more treatment choices. [Internet]. 2023 [cited 2023 Oct 3]. Available from: https://www.fda.gov/consumers/consumer-updates/biosimilar-and-interchangeable-biologics-more-treatment-choices
- Kay J. A ‘wind of change’ to biosimilars: the nor - SWITCH trial and its extension. J Intern Med. 2019;285(6):693–695. doi: 10.1111/joim.12896
- EMA. Biosimilars in the EU. Information guide for healthcare professionals [Internet]. 2019 [cited 2023 Mar 3]. Available from https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf.
- FDA. FDA approves first biosimilar to treat multiple sclerosis [Internet]. 2023 [cited 2023 Aug 30]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treat-multiple-sclerosis.
- EMA. Tyruko® (natalizumab) EPAR Medicine Overview. [Internet]. 2023 [cited 2023 Nov 8]. Available from: https://www.ema.europa.eu/en/documents/overview/tyruko-epar-medicine-overview_en.pdf
- Hemmer B, Wiendl H, Roth K, et al. Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis. JAMA Neurol. 2023;80(3):298.
- Schwab N, Schneider-Hohendorf T, Melzer N, et al. Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. Neurology. 2017;88(12):1197–1205.
- Tanaka M, Kinoshita M, Foley JF, et al. Body weight-based natalizumab treatment in adult patients with multiple sclerosis. J Neurol. 2015;262(3):781–782.
- Foley JF, Goelz S, Hoyt T, et al. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord. 2019;31:65–71. doi: 10.1016/j.msard.2019.03.017
- Serra López-Matencio JM, Pérez García Y, Meca-Lallana V, et al. Evaluation of natalizumab Pharmacokinetics and pharmacodynamics: toward individualized doses. Front Neurol. 2021;12:12. doi: 10.3389/fneur.2021.716548
- Shapiro RI, Plavina T, Schlain BR, et al. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (tysabri®) with endogenous IgG4. J Pharm Biomed Anal. 2011;55(1):168–175.
- Labrijn AF, Buijsse AO, van den Bremer ETJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27(8):767–771.
- Li J, Florian J, Campbell E, et al. Advancing biosimilar development using pharmacodynamic biomarkers in clinical pharmacology studies. Clin Pharmacol Ther. 2020;107(1):40–42.
- Visser SAG, Bueters TJH. Assessment of translational risk in drug research: role of biomarker classification and mechanism-based PKPD concepts. Eur J Pharmaceut Sci. 2017;109:S72–S77. doi: 10.1016/j.ejps.2017.08.006
- Maurer W, Jones B, Chen Y. Controlling the type I error rate in two‐stage sequential adaptive designs when testing for average bioequivalence. Stat Med. 2018;37(10):1587–1607. doi: 10.1002/sim.7614
- Khoy K, Mariotte D, Defer G, et al. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020;11:11. doi: 10.3389/fimmu.2020.549842
- FDA. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Guidance for industry [Internet]. 2016 [cited 2023 6 Apr]. Available from:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-data-support-demonstration-biosimilarity-reference-product
- Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
- Link J, Ramanujam R, Auer M, et al. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: a descriptive study of test results. PLoS One. 2017;12(2):e0170395.
- Dwyer CM, Jokubaitis VG, Stankovich J, et al. High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients. Ther Adv Neurol Disord. 2021;14:175628642199891. doi: 10.1177/1756286421998915